Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cancer Genetics stock

Own Cancer Genetics stock in just a few minutes.

Posted

Fact checked

Cancer Genetics, Inc is a biotechnology business based in the US. Cancer Genetics shares (CGIX) are listed on the NASDAQ and all prices are listed in US Dollars. Cancer Genetics employs 110 staff and has a trailing 12-month revenue of around USD$6.3 million.

How to buy shares in Cancer Genetics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Cancer Genetics. Find the stock by name or ticker symbol: CGIX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cancer Genetics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cancer Genetics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Cancer Genetics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cancer Genetics share price

Use our graph to track the performance of CGIX stocks over time.

Cancer Genetics shares at a glance

Information last updated 2021-02-23.
52-week rangeUSD$1.92 - USD$7.7
50-day moving average USD$4.4912
200-day moving average USD$3.7115
Wall St. target priceUSD$3
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.515

Buy Cancer Genetics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cancer Genetics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cancer Genetics financials

Revenue TTM USD$6.3 million
Gross profit TTM USD$3.6 million
Return on assets TTM -14.9%
Return on equity TTM -68.71%
Profit margin -71.5%
Book value $1.917
Market capitalisation USD$52.4 million

TTM: trailing 12 months

Shorting Cancer Genetics shares

There are currently 220,441 Cancer Genetics shares held short by investors – that's known as Cancer Genetics's "short interest". This figure is 208.6% up from 71,437 last month.

There are a few different ways that this level of interest in shorting Cancer Genetics shares can be evaluated.

Cancer Genetics's "short interest ratio" (SIR)

Cancer Genetics's "short interest ratio" (SIR) is the quantity of Cancer Genetics shares currently shorted divided by the average quantity of Cancer Genetics shares traded daily (recently around 1.2 million). Cancer Genetics's SIR currently stands at 0.18. In other words for every 100,000 Cancer Genetics shares traded daily on the market, roughly 180 shares are currently held short.

However Cancer Genetics's short interest can also be evaluated against the total number of Cancer Genetics shares, or, against the total number of tradable Cancer Genetics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cancer Genetics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Cancer Genetics shares in existence, roughly 50 shares are currently held short) or 0.0552% of the tradable shares (for every 100,000 tradable Cancer Genetics shares, roughly 55 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cancer Genetics.

Find out more about how you can short Cancer Genetics stock.

Cancer Genetics share dividends

We're not expecting Cancer Genetics to pay a dividend over the next 12 months.

Have Cancer Genetics's shares ever split?

Cancer Genetics's shares were split on a 1:30 basis on 25 October 2019. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cancer Genetics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Cancer Genetics shares which in turn could have impacted Cancer Genetics's share price.

Cancer Genetics share price volatility

Over the last 12 months, Cancer Genetics's shares have ranged in value from as little as $1.92 up to $7.7. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cancer Genetics's is 2.6505. This would suggest that Cancer Genetics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Cancer Genetics overview

Cancer Genetics, Inc., through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site